APU
SRPT icon

Alpine Partners USVI’s Sarepta Therapeutics SRPT Stock Holding History

Alpine Partners USVI’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-42,770
Closed -$2.02M – 38
2013
Q3 		$2.02M Buy
+42,770
New +$1.65M 7.57% 4

Other funds holding SRPT

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Alpine Partners USVI's SRPT Position: Q4 2013 in Review

Alpine Partners USVI sold out of Sarepta Therapeutics (SRPT) in Q4 2013, closing a stake of 42,770 shares — an estimated $2.02M sold.

Alpine Partners USVI first reported a position in SRPT in Q3 2013 and held it in 1 quarter. The position peaked at $2.02M in Q3 2013. 108 funds tracked by Wall St. Rank hold SRPT as of Q4 2013.

  • Alpine Partners USVI reported no remaining Sarepta Therapeutics position as of Q4 2013 after selling out during the quarter.
  • Alpine Partners USVI sold 42,770 Sarepta Therapeutics shares in Q4 2013, an estimated $2.02M.
  • Alpine Partners USVI first reported a position in Sarepta Therapeutics in Q3 2013 and held it in 1 quarter.
  • Alpine Partners USVI's Sarepta Therapeutics position peaked at $2.02M in Q3 2013.
  • 108 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2013.

Based on Alpine Partners USVI's 13F filing for Q4 2013, filed 14 Feb 2014.